GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,